Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

The Washington University

Status

Completed

Conditions

Glucose Metabolism Disorders

Treatments

Dietary Supplement: NMN supplement

Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT03151239

201701096

Details and patient eligibility

About

The purpose of the study is to understand the effect of the dietary supplement "Nicotinamide mononucleotide" on metabolic health in people.

Full description

This study is is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease. Accordingly, the investigators will evaluate the effect of NMN on how well the hormone insulin works to control blood sugar. The investigators will also look at the effects of NMN on blood lipids; body fat and liver fat; and other blood, fat tissue and muscle tissue markers of cardiovascular (heart) and metabolic health. Data from studies conducted in rodents have shown that NMN supplementation has beneficial effects on cardiovascular and metabolic health, but this has not yet been studied in people.

Enrollment

25 patients

Sex

Female

Ages

55 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Postmenopausal women 55-75 years old
BMI 25.0-44.9 kg/m²
Fasting plasma glucose concentration ≥100 mg/dl, OGTT 2 hour glucose ≥ 140 mg/dl, HbA1C ≥5.7%, or HOMA-IR ≥2.5

Exclusion criteria

Diabetes
Premenopausal or menopause <1 year
Persons who have received hormone replacement therapy within the past 6 months
Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period.
Structured exercise: ≥75 min/wk of vigorous exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥150 min/wk of low intensity physical activity (e.g., brisk walking).
Unstable weight (>3% change during the last 2 months before entering the study)
Significant organ system dysfunction or disease
Present cancer or history of cancer that has been in remission for <5 years
Polycystic ovary syndrome
Major psychiatric illness
Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study
Metal implants
Smokes cigarettes
Persons who consume >14 units of alcohol per week
Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.